Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Canadian Superior Energy Announces First Quarter 2010 Financial and Operating Results
May 13, 2010
http://www.cansup.com/pdf_files/May132010.pdf
CEL-SCI Corporation Reports Second Quarter 2010 Financial Results
Date : 05/17/2010 @ 4:18PM
Source : Business Wire
Stock : CEL-SCI Corporation (CVM)
http://ih.advfn.com/p.php?pid=nmona&article=42857045&symbol=CVM
CEL-SCI Corporation (NYSE AMEX: CVM) reports financial results for the quarter ended March 31, 2010.
CEL-SCI reported that net loss for the three months ended March 31, 2010 was ($0.7 million) versus a loss of ($2.1 million) during the same three months in fiscal year 2009. Net loss per share was ($0.01) for the three months ended March 31, 2010 versus a loss of ($0.02) during the same three months in fiscal year 2009. The loss during the quarter ended March 31, 2010 was reduced by a gain on derivative instruments of $4.5 million.
Net income available to shareholders for the six months ended March 31, 2010 was $17 million versus a loss of ($4.3 million) during the same six months in fiscal year 2009. Net income per share, basic was $0.09 for the six months ended March 31, 2010 versus a loss of ($0.03) during the same six months in fiscal year 2009. The gain on net income for the six months ended March 31, 2010 was due to derivative accounting.
R&D expenses for the three months ended March 31, 2010 totaled $3.3 million versus R&D expenses of $1.2 million for the same period in fiscal year 2009. R&D expenses for the six months ended March 31, 2010 totaled $6.1 million versus R&D expenses of $2.7 million for the same period in fiscal year 2009.
Geert Kersten, Chief Executive Officer said, “Expenditures during the past two quarters have been relatively high due to the preparations for the start of the pivotal Phase III trial with our cancer drug Multikine®. Net cash used during the quarter totaled approximately $4 million. Despite this we concluded the March 31, 2010 quarter in a very strong financial condition, with more than $34 million in cash and cash equivalents. We are very pleased to have the ability to self-fund our upcoming pivotal study, expected to be the largest head and neck cancer Phase III trial ever conducted, and are working closely with our partners Teva Pharmaceuticals and Orient Europharma towards a successful launch."
About Multikine Cancer Immunotherapy
CEL-SCI is developing Multikine for approval as a first-line indication in newly diagnosed head and neck cancer. To that end, the Company's planned Phase III clinical trial is an 800 patient randomized, controlled clinical study designed to demonstrate that administration of its cancer drug Multikine to head and neck cancer patients before they receive any other conventional cancer treatment will increase their overall survival. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery.
The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine and has granted CEL-SCI's Multikine an Orphan Drug Designation for the "neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN)". In early 2010 CEL-SCI finished the validation of its dedicated state of the art commercial-ready manufacturing facility for Multikine.
Multikine is the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.
Multikine is a patented defined mixture of naturally derived cytokines. It is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its L.E.A.P.S. technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. This investigational treatment is currently being tested in a clinical study at Johns Hopkins University. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
...
NexMed to Discuss P2/3 Protocol for NexACT®-Based Alprostadil Treatment for Raynaud’s Syndrome with the FDA
Date : 05/17/2010 @ 5:11PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&article=42858553&symbol=N%5ENEXM
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has granted the Company an Investigational New Drug application number for its NexACT-based alprostadil treatment for Raynaud’s syndrome, ahead of a pre-IND meeting in mid-July 2010 to discuss its proposed Phase 2/3 protocol. The Company is in late stage development for Vitaros, its topically applied NexACT-based alprostadil treatment for erectile dysfunction.
Raynaud's syndrome refers to a disorder in which the fingers or toes (digits) suddenly experience decreased blood circulation, and is characterized by color changes of the skin of the digits upon exposure to cold or emotional stress. The prevalence of Reynaud's syndrome in the general U.S. population is estimated to vary from 4–15%. Females are seven times more likely to develop the condition than men. For most patients, Raynaud’s syndrome is an inconvenience. However, chronic recurrent cases of Raynaud’s syndrome can result in atrophy of the skin, subcutaneous tissues and muscle. In rare cases it can cause ulceration and ischemic gangrene.
Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, “Given the disease characteristics, Raynaud’s syndrome is an appealing product opportunity for us and one that we believe can benefit strongly from the active ingredient in Vitaros, which is alprostadil, or prostaglandin E1 (PGE1), a potent vasodilator. With the safety and efficacy of the currently approved, injectable PGE1 already well demonstrated, together with NexMed’s existing safety and efficacy clinical database for Vitaros, our intention is to move our topical Raynaud’s product candidate directly into Phase 2/3 clinical testing as soon as possible. We look forward to our meeting with the FDA in mid-July to further discuss our clinical development plan for this potential new therapy.”
About NexMed
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT®-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.
Forward-Looking Statement Safe Harbor for NexMed
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including but not limited to, its ability to have the resources necessary to complete clinical testing and obtain regulatory approval for its products under development.
Publication in the Journal of the National Cancer Institute Demonstrates KRX-0401 (Perifosine) Single-Agent Potential in Neuroblastoma Tumors
Date : 05/17/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=42848470&symbol=N^KERX
Perifosine observed to be an effective novel agent in neuroblastoma cells in vitro and in vivo
Phase 1 data of single agent perifosine as a treatment for recurrent solid tumors in pediatric patients, including neuroblastoma patients, to be presented at ASCO
PR Newswire
NEW YORK, May 17
NEW YORK, May 17 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the publication of an article in the May 12th Journal of the National Cancer Institute, entitled "In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine," demonstrating the single agent activity of KRX-0401 (perifosine) in neuroblastoma tumor preclinical models. Neuroblastoma is the most common pediatric solid tumor. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits AKT activation in the phosphoinositide 3-kinase (PI3K) pathway, is currently being investigated in a Phase 1 study as a single agent treatment for recurrent solid tumors, including neuroblastoma, in pediatric patients.
The article states that activated AKT is a marker of decreased event-free or overall survival in neuroblastoma patients, and that the aim of this study was to investigate the effect of perifosine, an AKT inhibitor, as a single agent on neuroblastoma cell growth in vitro and in vivo. The preclinical study investigated the activity of perifosine on four human neuroblastoma cell lines, as well as on the survival, tumor growth, and activation status of AKT in mice bearing human neuroblastoma xenograft tumors. Perifosine showed a statistically significant reduction in neuroblastoma cell survival, slowed or regressed tumor growth, and increased survival in mice bearing neuroblastoma tumors. A decreased level of activated AKT was also observed in perifosine-treated neuroblastoma cells and xenograft tumors.
The investigators concluded that perifosine inhibited the activation of AKT and was an effective cytotoxic agent in neuroblastoma cells in vitro and in vivo, and that this data supports the future clinical evaluation of perifosine for the treatment of neuroblastoma tumors.
Ron Bentsur, Chief Executive Officer of Keryx, commented, "We find this data to be encouraging, and we look forward to our upcoming ASCO presentation in which we will have Phase 1 single agent perifosine data in pediatric patients, including patients with neuroblastoma. Mr. Bentsur added, "While our Phase 3 programs for perifosine in metastatic colorectal cancer and multiple myeloma are moving forward, it is also exciting to see data that can potentially provide important clinical paths for the treatment of pediatric cancer patients worldwide."
A copy of the article can be obtained at http://www.ncbi.nlm.nih.gov/pubmed/20463309.
Perifosine is currently in Phase 3 clinical development for refractory advanced colorectal cancer and multiple myeloma, both of these Phase 3 programs being conducted under Special Protocol Assessment (SPA) agreements with the FDA with Fast Track designations obtained for both studies. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. in the United States, Canada and Mexico.
About Neuroblastoma
Neuroblastoma is the most common pediatric solid tumor and is also the most frequently diagnosed neoplasm during infancy. Neuroblastoma accounts for more than 7% of malignancies in patients younger than 15 years and causes 15% of all pediatric oncology deaths. Activated AKT is believed to be highly expressed in poor prognosis neuroblastoma tumors. Infants, even those with metastatic disease, may experience complete regression of their disease with single low-dose chemotherapy or observation alone in carefully selected circumstances. However, poor prognosis patients, usually older than 18 months and who have extensive metastatic disease, may initially respond to intensive multimodality chemotherapy, but the tumors eventually recur and become resistant to chemotherapy. Approximately half of all neuroblastoma patients are diagnosed with high-risk poor prognosis disease, and these patients have an overall survival rate of less than 40%. Therefore, a major challenge is to improve the treatment efficacy in high-risk neuroblastoma patients.
There are currently no FDA approved drugs for the treatment of neuroblastoma.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from ongoing clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the NIH website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
Publication in the Journal of the National Cancer Institute Demonstrates KRX-0401 (Perifosine) Single-Agent Potential in Neuroblastoma Tumors
Date : 05/17/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=42848470&symbol=N^KERX
Perifosine observed to be an effective novel agent in neuroblastoma cells in vitro and in vivo
Phase 1 data of single agent perifosine as a treatment for recurrent solid tumors in pediatric patients, including neuroblastoma patients, to be presented at ASCO
PR Newswire
NEW YORK, May 17
NEW YORK, May 17 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the publication of an article in the May 12th Journal of the National Cancer Institute, entitled "In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine," demonstrating the single agent activity of KRX-0401 (perifosine) in neuroblastoma tumor preclinical models. Neuroblastoma is the most common pediatric solid tumor. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits AKT activation in the phosphoinositide 3-kinase (PI3K) pathway, is currently being investigated in a Phase 1 study as a single agent treatment for recurrent solid tumors, including neuroblastoma, in pediatric patients.
The article states that activated AKT is a marker of decreased event-free or overall survival in neuroblastoma patients, and that the aim of this study was to investigate the effect of perifosine, an AKT inhibitor, as a single agent on neuroblastoma cell growth in vitro and in vivo. The preclinical study investigated the activity of perifosine on four human neuroblastoma cell lines, as well as on the survival, tumor growth, and activation status of AKT in mice bearing human neuroblastoma xenograft tumors. Perifosine showed a statistically significant reduction in neuroblastoma cell survival, slowed or regressed tumor growth, and increased survival in mice bearing neuroblastoma tumors. A decreased level of activated AKT was also observed in perifosine-treated neuroblastoma cells and xenograft tumors.
The investigators concluded that perifosine inhibited the activation of AKT and was an effective cytotoxic agent in neuroblastoma cells in vitro and in vivo, and that this data supports the future clinical evaluation of perifosine for the treatment of neuroblastoma tumors.
Ron Bentsur, Chief Executive Officer of Keryx, commented, "We find this data to be encouraging, and we look forward to our upcoming ASCO presentation in which we will have Phase 1 single agent perifosine data in pediatric patients, including patients with neuroblastoma. Mr. Bentsur added, "While our Phase 3 programs for perifosine in metastatic colorectal cancer and multiple myeloma are moving forward, it is also exciting to see data that can potentially provide important clinical paths for the treatment of pediatric cancer patients worldwide."
A copy of the article can be obtained at http://www.ncbi.nlm.nih.gov/pubmed/20463309.
Perifosine is currently in Phase 3 clinical development for refractory advanced colorectal cancer and multiple myeloma, both of these Phase 3 programs being conducted under Special Protocol Assessment (SPA) agreements with the FDA with Fast Track designations obtained for both studies. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. in the United States, Canada and Mexico.
About Neuroblastoma
Neuroblastoma is the most common pediatric solid tumor and is also the most frequently diagnosed neoplasm during infancy. Neuroblastoma accounts for more than 7% of malignancies in patients younger than 15 years and causes 15% of all pediatric oncology deaths. Activated AKT is believed to be highly expressed in poor prognosis neuroblastoma tumors. Infants, even those with metastatic disease, may experience complete regression of their disease with single low-dose chemotherapy or observation alone in carefully selected circumstances. However, poor prognosis patients, usually older than 18 months and who have extensive metastatic disease, may initially respond to intensive multimodality chemotherapy, but the tumors eventually recur and become resistant to chemotherapy. Approximately half of all neuroblastoma patients are diagnosed with high-risk poor prognosis disease, and these patients have an overall survival rate of less than 40%. Therefore, a major challenge is to improve the treatment efficacy in high-risk neuroblastoma patients.
There are currently no FDA approved drugs for the treatment of neuroblastoma.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from ongoing clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the NIH website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
Greek leader considers action against US banks
Greek leader says legal action against US investment banks possible for role in debt crisis
Sunday May 16, 2010, 12:34 pm EDT
http://finance.yahoo.com/news/Greek-leader-considers-action-apf-3405375447.html?x=0&sec=topStories&pos=main&asset=&ccode=
ATHENS, Greece (AP) -- Greek Prime Minister George Papandreou declared he is not ruling out taking legal action against U.S. investment banks for their role in creating the spiraling Greek debt crisis.
Both the Greek government and its citizens have blamed international banks for fanning the flames of the debt crisis with comments about Greece's likely default, actions that are causing the country's borrowing costs to soar.
"I wouldn't rule out that (legal action) might be a recourse. But we need to let due process (take its course) and then make our judgments once we get the results from the investigations," Papandreou said in a CNN interview broadcast Sunday.
Papandreou also said a parliamentary investigation will examine the rapid swelling of Greece's debt and international banking practices to examine whether the financial sector engaged in "fraud and lack of transparency."
The European Union and the International Monetary fund have approved a euro110 billion ($136 billion) bailout package for Greece, part of an overall euro750 billion ($1 trillion) rescue loan package to protect the euro, the common currency of 16 European nations.
The Greek leader also urged more regulation of the markets which, in his view, are now betting against the European governments that have poured billions into them since the global financial crisis began in 2008.
Some European governments plan to push for tighter regulation of hedge funds this week -- a move opposed by Britain, home to the financial hub of London.
Papandreou also tried to counter criticism, expressed mainly in Germany, that Greeks are getting a free ride and rejected widespread international skepticism about Greece's ability to pay back its loans. Greek debt is scheduled to exceed 140 percent of its economic output in 2012.
"We are paying back the loans we are getting ... this saying that 'we are handing out money to Greece' is not true," he told the CNN show "Fareed Zakaria GPS." "It is very easy to scapegoat Greece and Greece bashing very often gets entangled in regional politics."
He insisted his government has made the unpopular but necessary decision to implement austerity measures.
"We are ready to make the changes ... we have made our mistakes. We are living up to this responsibility. But at the same time, give us a chance," Papandreou said.
Still, another top German economist expressed doubts Sunday about Greece's ability to repay.
Deutsche Bank AG's Chief Executive Josef Ackermann created an uproar Thursday for mentioning the possibility that Greece might have to restructure its debt -- but Dekabank's chief economist, Ulrich Kater, was quoted as agreeing with him Sunday in the German news website Handelsblatt.
"It will be very, very difficult for Greece to orderly repay its debt," Kater was quoted as saying, adding that Greece's new austerity measures and its lack of competitiveness were dooming the country's prospects for economic growth, making debt reduction difficult.
Despite widespread anger about tax hikes and other austerity measures imposed by Papandreou's Socialist government, his party still enjoys more support than its predecessor, the discredited conservative party.
According to a poll published Sunday in conservative-leaning newspaper Kathimerini, Papandreou's popularity has plunged from 53 percent in January to 43 percent in May. The same poll showed that opposition leader Antonis Samaras has sunk from 26 percent approval in February to 18 percent in May.
On the other hand, 76 percent of respondents also say they are unsatisfied with the Socialist government's performance.
The poll was conducted May 6-10 with a sample of 1,006. Its margin of error was plus or minus 3.2 percent.
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
http://www.finanznachrichten.de/nachrichten-2010-05/16904128-keryx-biopharmaceuticals-announces-upcoming-corporate-presentations-008.htm
NEW YORK, May 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following May Investor conferences:
Monday, May 17, 2010 - 3:40 p.m. GMT (10:40 am EDT). ----------------------------------------------------
6th Annual Rodman&Renshaw Global Healthcare Conference Grosvenor House Hotel London, England
Thursday, May 27, 2010 - 3:00pm EDT -----------------------------------
2010 Citi Global Healthcare Conference New York Hilton New York, NY
A live audio webcast of Mr. Bentsur's presentations will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com/. An archived version of each webcast will be available following the conclusion of the live presentation.
In addition, on May 17, 2010, the Company will be participating in a Multiple Myeloma panel discussion at the Brean Murray, Carret&Co. 2010 Life Sciences Summit, to be held in New York City.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: lfischer@keryx.com
Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director - Investor Relations of Keryx
Biopharmaceuticals, Inc., +1-212-531-5965, lfischer@keryx.com
Web Site: http://investors.keryx.com/
© 2010 PR Newswire
##################################################################
##################################################################
KERX - 2010 NEWS (updated)
01/05/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=40967159&symbol=NASDAQ%3AKERX
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Registration Program of Zerenex in patients with end-stage renal disease (ESRD)
##################################################################
01/25/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=41242064&symbol=NASDAQ%3AKERX
Keryx Reports Statistically Significant Benefit in Survival from Updated Results on the clinical activity of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, in combination with capecitabine (Xeloda®) as a treatment for advanced, metastatic colon cancer.
##################################################################
01/29/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=41314106&symbol=N^KERX
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's")
##################################################################
02/03/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=41377888&symbol=N^KERX
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in patients with refractory metastatic colorectal cancer.
##################################################################
04/05/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42251074&symbol=N^KERX
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
##################################################################
04/08/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42299718&symbol=N^KERX
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Refractory Advanced Colorectal Cancer
##################################################################
04/15/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42392688&symbol=N^KERX
Keryx Biopharmaceuticals Reports Updated Long-Term Data of Zerenex (ferric citrate) Presented at National Kidney Foundation (NKF) 2010 Spring Clinical Meetings
##################################################################
Date : 05/06/2010 @ 8:00AM
http://ih.advfn.com/p.php?pid=nmona&article=42688680&symbol=KERX
Keryx Biopharmaceuticals Initiates Phase 3 Registration Program of Zerenex (ferric citrate) for the Treatment of Patients with Hyperphosphatemia
##################################################################
KERX - 2010 NEWS (updated)
01/05/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=40967159&symbol=NASDAQ%3AKERX
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Registration Program of Zerenex in patients with end-stage renal disease (ESRD)
##################################################################
01/25/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=41242064&symbol=NASDAQ%3AKERX
Keryx Reports Statistically Significant Benefit in Survival from Updated Results on the clinical activity of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, in combination with capecitabine (Xeloda®) as a treatment for advanced, metastatic colon cancer.
##################################################################
01/29/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=41314106&symbol=N^KERX
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's")
##################################################################
02/03/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=41377888&symbol=N^KERX
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in patients with refractory metastatic colorectal cancer.
##################################################################
04/05/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42251074&symbol=N^KERX
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
##################################################################
04/08/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42299718&symbol=N^KERX
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Refractory Advanced Colorectal Cancer
##################################################################
04/15/2010 @ 8:30AM
http://ih.advfn.com/p.php?pid=nmona&article=42392688&symbol=N^KERX
Keryx Biopharmaceuticals Reports Updated Long-Term Data of Zerenex (ferric citrate) Presented at National Kidney Foundation (NKF) 2010 Spring Clinical Meetings
##################################################################
Date : 05/06/2010 @ 8:00AM
http://ih.advfn.com/p.php?pid=nmona&article=42688680&symbol=KERX
Keryx Biopharmaceuticals Initiates Phase 3 Registration Program of Zerenex (ferric citrate) for the Treatment of Patients with Hyperphosphatemia
##################################################################
NexMed, Inc. Q1 2010 Earnings Call Transcript
May 14, 2010
http://seekingalpha.com/article/205198-nexmed-inc-q1-2010-earnings-call-transcript?source=feed
ITC affirms Emcore violated Avago patent
14.05.2010 00:04
http://www.finanznachrichten.de/nachrichten-2010-05/16898270-itc-affirms-emcore-violated-avago-patent-020.htm
WASHINGTON, May 13 (Reuters) - The International Trade Commission affirmed on Thursday a ruling that Emcore violated a patent owned by Avago Technologies.
The trade panel, which often hears patent disputes that involve imported products, upheld a decision by one of its administrative law judges, who had ruled in March that Emcore infringed an Avago patent to make devices it imported.
The commission also said that it would seek comment on barring the infringing devices from import into the United States.
The patent in question is used in optoelectronic devices, which are used for data communications for core routing and enterprise networking, Avago said on its web site.
(Editing by Carol Bishopric) Keywords: EMCORE AVAGO/PATENT
(Diane Bartz; Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com)
COPYRIGHT
Copyright Thomson Reuters 2010. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
Quarterly Report (10-Q)
For the quarterly period ended March 31, 2010
Date : 05/11/2010 @ 5:08PM
Source : Edgar (US Regulatory)
Stock : (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=42770881&symbol=N^KERX
...
There were 58,585,555 shares of the registrant’s common stock, $0.001 par value, outstanding as of May 5, 2010.
...
KERX -
http://www.finviz.com/quote.ashx?t=kerx&ty=c&ta=0&p=d
12-May-10 // Reiterated // Rodman & Renshaw // Mkt Outperform $6 >> $8
11-May-10 // Reiterated // Ladenburg Thalmann // Buy $5 >> $8
EMCORE Corporation F2Q10 (Qtr End 03/31/10) Earnings Call Transcript
May 12, 2010
http://seekingalpha.com/article/204729-emcore-corporation-f2q10-qtr-end-03-31-10-earnings-call-transcript?source=feed
...it's time!
May 12-15, 2010 - Denver, Colorado
NewCardio to Demonstrate the Innovative CardioBip at the Heart Rhythm Society Annual Meeting
Date : 05/07/2010 @ 8:00AM
Source : PR Newswire
Stock : Newcardio (BB) (NWCI)
http://ih.advfn.com/p.php?pid=nmona&article=42710914&symbol=NWCI
Heart Rhythm Society Guests Will Have the Opportunity to See and Use NewCardio's Unique and Patented Solution For Remote Wireless 12-lead Detection And Monitoring of Atrial Fibrillation and Myocardial Ischemia
PR Newswire
SANTA CLARA, Calif., May 7
SANTA CLARA, Calif., May 7 /PRNewswire-FirstCall/ --
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, will unveil its patented CardioBip™ technology for remote wireless 12-lead detection and monitoring of atrial fibrillation, ischemia and other cardiovascular events at the Heart Rhythm Society (HRS) 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.
NewCardio will be at booth number 2147, giving conference attendees the opportunity to learn about NewCardio's unique 3-D platform technology: CardioBip, a unique, hand-held device that provides an effective, solution for ECG remote monitoring; Cardio3KG™, advanced software which provides quantitative analyses of cardiac electrical activity, with improved sensitivity and specificity over the standard 12-lead ECG for diagnosis of acute coronary events; and QTinno™ , a software solution that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety in drug development. In addition, NewCardio personnel will be on-hand to demonstrate the CardioBip, both at the Company's booth and on May 13th in a suite at the Hyatt Regency Denver, adjacent to the Denver Convention Ctr where HRS is held. Session attendees can utilize the CardioBip on themselves to see first-hand the simplicity and effectiveness of the technology.
HRS is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. The Annual Scientific Sessions attract more than 9,000 professionals representing the allied specialties of cardiac pacing and cardiac electrophysiology. More information is available at http://www.hrsonline.org/Sessions/ on the internet.
Images of NewCardio's CardioBip are available on the internet at http://www.newcardio.com/products-cardio-bip.php .
NewCardio's CEO, Branislav Vajdic, PhD., commented, "CardioBip is the first remote, wireless, non-invasive device which provides accurate 12-lead ECG results, and as such we believe it will propel remote cardiac monitoring to an entirely new level. This is the culmination of several years of work to advance this technology, and we are excited to share this significant clinical and technological advancement with scientists, medical professionals and industry leaders at the HRS Annual Scientific Sessions. With its 3-D technology, CardioBip will provide important data that addresses significant problems with the diagnosis and treatment of chronic cardiac conditions."
In addition, and as previously announced, the HRS has accepted an abstract detailing the superior performance of NewCardio's CardioBip, particularly in patients with atrial fibrillation for its oral presentation. The abstract, titled "Three-dimensional Atrial Signal Reconstruction Facilitates Remote Detection Of Atrial Fibrillation," was written by Alexei Shvilkin, MD, PhD, Dejan Vukajlovic, MD, Vladan Vukcevic, MD, Ihor Gussak, MD, PhD, Bosko Bojovic, PhD, Uros Mitrovic, MS and Goran Simic, MS. The abstract discusses the use of CardioBip for improved atrial fibrillation (AF) monitoring and detection, highlighting a new AF detection algorithm based on NewCardio's proprietary 3-D ECG processing platform.
The CardioBip is a unique, hand-held device that provides a solution for ECG remote monitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop. What makes CardioBip unique is its extreme ease of use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs. The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device's electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms. The device is not currently approved for sale or distribution in the United States. On January 12, 2010, the U.S. Patent and Trademark Office issued patent 7,647,093, titled "Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing." This represents the core patent for CardioBip. Additional patent applications covering the CardioBip have been submitted.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hayden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio, Inc.
Current report filing (8-K)
Date : 05/11/2010 @ 5:11PM
Source : Edgar (US Regulatory)
Stock : (NWCI)
http://ih.advfn.com/p.php?pid=nmona&article=42771158&symbol=NB^NWCI
As previously reported by NewCardio, Inc. (the “Company”), in its current report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on July 30, 2009, the Company entered into a $3 million credit line arrangement (the “Credit Line”), on July 30, 2009, pursuant to a Securities Purchase Agreement (the “SPA”), pursuant to which purchasers purchased 12% Secured Revolving Debentures Due March 31, 2011(the “Debentures”) and, in connection therewith, (x) were issued 750,000 five year common stock purchase warrants with an exercise price of $0.01 per share, and (y) will be issued upon each draw down under the Credit Line, for each $1.00 advanced under the Credit Line, additional five year common stock purchase warrants exercisable at a price equal to 100% of the average VWAPs for the prior five trading days (the “Draw Down Warrants”). The SPA and the Debentures were amended on December 30, 2009, to extend for two months the period during which advances are available under the credit line and its maturity date to May 2011. The Draw Down Warrants have full-ratchet price protection with respect to future Draw Down Warrants issued under the Credit Line and future issuances of equity securities by the Company (subject to certain specific exceptions). The warrants also have cashless exercise provisions and are subject to forced cashless exercise in the event that the Company’s common stock is trading at three times the VWAP for the 20 trading days prior to issuance of the warrants. All interest under the Debentures accrues and is payable upon maturity. Forms of the warrants and the debenture are exhibits to the SPA filed as an exhibit to the Company’s current report on Form 8-K, filed with the SEC on July 30, 2009.
On May 11, 2010, the Company completed a closing on a $500,000 advance under the Credit Line and issued Draw Down Warrants for the purchase of 500,000 shares of the Company’s common stock at a price per share of $1.24.
Quarterly Report (10-Q) - for the quarterly period ended March 31, 2010
Date : 05/11/2010 @ 4:59PM
Source : Edgar (US Regulatory)
Stock : (NWCI)
http://ih.advfn.com/p.php?pid=nmona&article=42770724&symbol=NB^NWCI
Quarterly Report (Form 10-Q)
http://ih.advfn.com/p.php?pid=nmona&article=42781942
The number of shares of common stock, par value $0.01, outstanding as of May 10, 2010 is 8,980,634.
Zoom Technologies Reports First Quarter 2010, Results Exceed Revenue and Net Income Guidance
Date : 05/12/2010 @ 8:00AM
Source : MarketWire
Stock : Zoom Technologies (ZOOM)
http://ih.advfn.com/p.php?pid=nmona&article=42781195
BEIJING -- (Marketwire)
05/12/10
Zoom Technologies, Inc. (NASDAQ: ZOOM)
Quarterly Highlights:
-- Net revenue increased 77% year over year to $50.98 million
-- Net income grew 113% over last year to $1.90 million
-- Sold $4.63 million of proprietary LEIMONE brand phones
Guidance:
-- Second Quarter 2010 net revenue between $56 and $62 million
-- Second Quarter 2010 net income between $1.8 and $2.2 million
-- Increased full year 2010 net revenue guidance between $250 and
$270 million
-- Increased full year 2010 net income guidance between $11.5 and
$12.5 million
Zoom Technologies, Inc. (NASDAQ: ZOOM), a leading
China-based manufacturer of mobile phones and other mobile electronic
products, reported financial results for the first quarter ended March 31,
2010.
Mr. Lei Gu, Chairman and Chief Executive Officer of Zoom Technologies,
commented, "Our first quarter results exceeded our expectations and reflect
the success of our business plans in the dynamic mobile phone industry in
China. We reported another quarter of tremendous year over year revenue
growth and are encouraged to start 2010 with a sequentially higher net
income then in the historically strongest fourth quarter. Our strong
position in the momentous and growing Chinese cell phone manufacturing
market and the success of our own brand LEIMONE phones led to this exciting
financial performance which we expect to continue going forward."
For the first quarter of 2010, Zoom reported net revenue of $50.98 million,
up 77% over $28.82 million for the first quarter 2009. Against the
seasonally slower first quarter, sales for the 2010 first quarter came in
stronger than expected. The year over year revenue growth was primarily
due to an increase in orders from domestic EMS customers and an increase in
sales of Zoom's own branded LEIMONE phones. Net income for the first
quarter ended March 31, 2010 was $1.90 million compared to net income of
$0.89 million for the first quarter of 2009, and even surpassing the $1.89
million in the fourth quarter of 2009, which is historically our strongest
quarter.
Gross profit for the first quarter 2010 was $4.18 million, up 56% from
$2.68 million for the first quarter 2009 and up 62% from the fourth quarter
2009. Gross margin for the first quarter of 2010 was 8.2%, up from 6.0%
for the full year 2009. The increase in gross margins for the first
quarter 2010 compared to the full year 2009 is partially due to sales of
Zoom's own brand phones which carry higher margins. Net margin for the
first quarter 2010 was 3.7%, an increase from 3.2% in the first quarter of
2009.
Mr. Gu continued, "We are also delighted to have recently executed a share
exchange agreement with Nollec Wireless Company which we expect to close by
the end of May 2010. Nollec Wireless is capable of designing in any and all
mobile phone platforms, and has experience in global launches and delivery
of phone models. The acquisition of Nollec Wireless will strengthen Zoom's
position in the mobile phone business due to Nollec's strong R&D background
in all aspects of mobile phone design such as chipsets, electronic hardware
design, application software development, mechanical design and system
design. We are extremely excited that Nollec can contribute to develop new
and more technologically advanced LEIMONE mobile phones including the
Android OS phone expected to be released in the third quarter 2010."
Looking ahead, Mr. Gu remarked, "We will continue to focus on our mobile
manufacturing business in 2010, as the market opportunity in China is in
high demand and we are ready to take advantage of the foreseeable growth in
China's mobile market. For the second quarter 2010, we expect net revenue
to be between $56 and $62 million and net income is expected to in the
range of $1.8 and $2.2 million. For the full year 2010, we are upwardly
revising our guidance and now expect net revenue to be between $250 and
$270 million and net income between $11.5 million to $12.5 million. We
previously guided full year 2010 net revenue to be between $240 and $260
million, and net income to be between $10.5 and $11.5 million."
Conference Call Details
A conference call to review the results will begin at 9:00 a.m. US Eastern
Time on May 12 (9:00 p.m. Beijing Time). The dial-in numbers are +
1-877-407-0789 for US domestic callers and + 1-201-689-8562 for
international callers. A telephonic replay of the call will be available
through May 26, 2010. The replay dial-in numbers are + 1-877-660-6853 for
US domestic callers and + 1-201-612-7415 for international callers. The
account number to access the replay is 3055 and the conference ID number is
350350.
About Zoom Technologies, Inc.
Zoom Technologies is a holding company with subsidiaries that engage in the
manufacturing, research and development, and sale of electronic and
telecommunication products for 3rd generation mobile phones, wireless
communication circuitry, and related software products. Zoom Technologies'
subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which
offers highly customized and high quality Electronic Manufacturing Service
(EMS) for Original Equipment Manufacturer (OEM) customers as well as its
own brand under the brand name of Leimone. The company's products are both
exported and sold domestically. For more information about Zoom
Technologies please visit Zoom's corporate website at
http://www.zoomleimone.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward looking
statements" that involve risks and uncertainties. These include statements
about our expectations, plans, objectives, assumptions or future events,
including our expansion in other 3G enabled mobile phones and the
acquisition of Leimone Culture, which may require shareholder approval that
cannot be assured. You should not place undue reliance on these
forward-looking statements. Information concerning factors that could cause
our actual results to differ materially from these forward-looking
statements can be found in our periodic reports filed with the Securities
and Exchange Commission. We undertake no obligation to publicly release
revisions to these forward-looking statements to reflect future events or
circumstances or reflect the occurrence of unanticipated events.
...
KERX -
http://www.finviz.com/quote.ashx?t=kerx&ty=c&ta=0&p=d
11-May-10 // Reiterated // Ladenburg Thalmann // Buy $5 >> $8
As of May 6, 2010, 77,852,154 shares of Cardium's common stock were outstanding.
http://ih.advfn.com/p.php?pid=nmona&article=42746827&symbol=CXM
Cardium Reports on First Quarter 2010 Financial Results and Recent Developments
Date : 05/10/2010 @ 4:15PM
http://ih.advfn.com/p.php?pid=nmona&article=42746827&symbol=CXM
PR Newswire
SAN DIEGO, May 10
SAN DIEGO, May 10 /PRNewswire-FirstCall/ --
Cardium Therapeutics (NYSE Amex: CXM) today reported highlights and financial results for its first quarter ended March 31, 2010. Highlights of the quarter and recent developments include:
Completion of a registered direct investment of Cardium's common stock with institutional and retail investors in 2010 for gross proceeds of $11.3 million ($10.4 million net after placement fees and offering expenses);Agreement with bioRASI, an international contract research organization, to assist the Company to explore more rapid and cost effective opportunities to advance its cardiovascular biologic candidate, Generx®, as a front-line therapy for patients with coronary artery disease in newly-industrializing markets in Eastern Europe, Asia and Latin America;Continued commercialization activities in preparation for market launch of Cardium's Excellagen™ formulated collagen gel product candidate, which is pending 510(k) clearance with the U.S. Food and Drug Administration (FDA), and for patients with dermal wounds, which can include diabetic ulcers, pressure ulcers, venous ulcers, tunneled/undermined wounds, surgical and trauma wounds, second degree burns, and other types of wounds;Advancement towards commercial launch the Company's MedPodium™ over-the-counter advanced skin care line intended to provide a first line of defense for individuals at risk for foot ulcers and that will enhance and expand Cardium's product portfolio beyond the current Excellagen product candidate platform;Continued identification and evaluation of innovative and capital-efficient product opportunities and strategic partnership opportunities for the Company's current product candidates as they are advanced and corresponding valuations are established.(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
Financial Report
For the first quarter ended March 31, 2010, the Company reported a net loss of $1.0 million, or $(0.02) per share, compared to a net loss of $14.7 million, or $(0.31) per share for the same period in 2009. Total loss from operations for first quarter 2010 was $1.5 million compared to $2.5 million for first quarter 2009. The first quarter 2010 financial results also include a $437,000 favorable adjustment to income for the non-cash change in fair market value of certain common stock warrants we recorded as derivative liabilities upon the adoption of ASC 815 (formerly Emerging Issues Task Force EITF 07-05), recorded in "Change in Fair Value of Derivative Liabilities."
Research and development costs for the three months ended March 31, 2010 totaled $520,000 and general and administrative expenses were $961,000, compared to $1.2 million and $1.3 million, respectively, for the same period last year. The decrease in research and development costs for first quarter 2010 was primarily due to a reduction in costs as a result of the completion of the Phase 2b clinical study for Cardium's Excellarate product candidate.
As of March 31, 2010, the Company had $11.8 million in cash and cash equivalents and $1.4 million in restricted cash compared to $1.4 million and $400,000, respectively, for the same period last year. The Company's working capital at March 31, 2010 was $11.1 million (excluding $4.4 million of non-cash derivative liabilities for warrants from the calculation). During first quarter 2010, the Company completed a common stock offering with institutional and retail investors resulting in gross proceeds of $11.3 million and net proceeds of $10.4 after deduction of placement fees and offering expenses. As of May 6, 2010, 77,852,154 shares of Cardium's common stock were outstanding.
About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the U.S. Food and Drug Administration (the "FDA") will grant marketing clearance of the Excellagen product candidates or that we or a partner can successfully introduce these or additional products into advanced wound care markets; that Excellagen, Excellarate or our other candidates will prove to be sufficiently safe and effective, or that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, or that clinical studies even if successful will lead to product advancement or partnering; that the Excellagen or Excellarate product candidates offer the potential for simpler or more cost-effective treatment for physicians and patients than other FDA-approved products that currently are or will be on the market; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the commercialization of Generx in the U.S. or other markets; that our product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that our clinical study programs can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that the FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.
Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2010 Cardium Therapeutics, Inc. All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.
Cardium Therapeutics™ and Generx® and MedPodium™ are trademarks of Cardium Therapeutics, Inc.
Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™ and Osteorate™
are trademarks of Tissue Repair Company.
Opexa Strengthens Tovaxin® Patent Estate Through Issuance of Key Patents
Date : 05/11/2010 @ 8:30AM
Source : Business Wire
Stock : Opexa Therapeutics, Inc. (OPXA)
http://ih.advfn.com/p.php?pid=nmona&article=42759013&symbol=OPXA
pexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a personalized T-cell therapy for multiple sclerosis (MS), announced today that two of its key patents have been issued by the U.S. Patent and Trademark Office, with a third patent expected to issue later this month based on a received Notice of Allowance. These issued and allowed patents strengthen the Opexa patent estate related to its T-cell vaccine franchise.
The newly issued patents are U.S. Patent Nos. 7,695,713 and 7,658,926, the granted claims of which are directed to Opexa’s proprietary process for manufacturing its T-cell vaccines as well as to compositions of such vaccines having reactivity to critical MS antigens. Additionally, a Notice of Allowance has also been received for Opexa’s U.S. Patent Application Serial No. 10/520,296, which is directed to T-cell vaccines based on autoreactive T-cell receptor epitopes found in a significant percentage of MS patients.
“Strengthening our patent position in the area of T-cell technology has been a key objective for us over the past twelve months and is strategically important for Opexa’s long term value,” commented Neil K. Warma, President and Chief Executive Officer of Opexa. “Our T-cell technology is the backbone of the Tovaxin development program which is in late clinical development for the treatment of MS. We view intellectual property protection as critical for maintaining and enhancing our long term competitive position,” added Mr. Warma.
About Opexa
Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company’s leading therapy, Tovaxin®, is a personalized cellular immunotherapy treatment that is in clinical development for multiple sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.
Opexa completed its 150 patient Tovaxin for Early Relapsing Multiple Sclerosis (TERMS) Phase 2b clinical study in late 2008 which was one of the first clinical studies investigating an autologous T-cell therapy in MS patients. Data from this clinical study show evidence that Relapsing Remitting MS (RRMS) patients treated with Tovaxin saw overall clinical, MRI, and immunological benefits over the placebo group, including statistical significance for decrease in the Annualized Relapse Rate (ARR), improvement in disability score (EDSS), and improvement in quality of life measures (MSQLI), as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.
Cautionary Statement Relating to Forward - Looking Information for the Purpose of "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “expects,” “believes,” “anticipates,” “estimates,” “may,” “could,” “intends,” and similar expressions are intended to identify forward-looking statements. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial payments, returns, royalties, performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: market conditions, our capital position, the ability of the Company to enter into and benefit from a partnering arrangement for the Company's product candidate, Tovaxin, on reasonably satisfactory terms (if at all), and our dependence (if partnered) on the resources and abilities of any partner for the further development of Tovaxin, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of developing a marketable product, our ability to raise additional capital to continue our treatment development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights (including for Tovaxin), the risk of litigation regarding our intellectual property rights, the success of third party development and commercialization efforts with respect to products covered by intellectual property rights transferred by the Company, our limited manufacturing capabilities, our dependence on third-party manufacturers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date made. We assume no obligation or undertaking to update any forward-looking statements to reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in the reports filed with the Securities and Exchange Commission.
NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT® Technology to Enhance the Bioavailabili...
Date : 05/10/2010 @ 5:19PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&article=42748246&symbol=NEXM
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced data from a pre-clinical study examining the subcutaneous delivery of rituximab, the first FDA-approved therapeutic antibody for the treatment of cancer in the United States. The study results showed that animals receiving subcutaneous injections of rituximab, incorporated with NexACT, demonstrated a 46% enhancement in bioavailability over rituximab, alone.
Rituximab is a cancer medication that interferes with the development of cancer cells, slowing their growth and spread in the body. Delivered via intravenous infusion, rituximab is the active drug in Rituxan®, currently marketed by Genentech and Biogen IDEC, and prescribed to treat Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis (RA).
Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, “The ability of the NexACT technology to successfully deliver rituximab subcutaneously in a pre-clinical setting may open the door to improving the delivery of other therapeutic antibodies, which the Company is in the process of studying. The use of human or humanized monoclonal antibodies, therapeutically, was a major breakthrough in the field of medicine. If the NexACT technology can ultimately be shown to lower the amount of antibody administered while improving the route of delivery and minimizing side effects, NexACT could potentially revolutionize the use of these drugs in the future. We look forward to advancing our work in this area and to the further studies that will be needed to validate these results in humans.”
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.
Rituxan® is a registered trademark of Biogen IDEC.
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including but not limited to its ability to obtain and/or NexMed’s ability to pursue its development strategy and the ability to replicate results from its preclinical research with the NexACT technology in later human clinical studies.
Zoom Technologies to Report First Quarter 2010 Financial Results
May 10, 2010 14:47 ET
http://www.marketwire.com/press-release/Zoom-Technologies-to-Report-First-Quarter-2010-Financial-Results-NASDAQ-ZOOM-1257391.htm
BEIJING--(Marketwire - May 10, 2010) - Zoom Technologies, Inc. (NASDAQ: ZOOM), a leading China based manufacturer of mobile phones and other mobile electronic products, today announced it will release first quarter 2010 financial results for the period ended March 31, 2010, before the market opens on Wednesday, May 12, 2010.
A conference call to review the results will begin at 9:00 a.m. US Eastern Time on May 12 (9:00 p.m. Beijing Time). The earnings call will be hosted by Chief Financial Officer, Anthony Chan.
The dial-in numbers are + 1-877-407-0789 for US domestic callers and + 1-201-689-8562 for international callers. A telephonic replay of the call will be available through May 26, 2010. The replay dial-in numbers are + 1-877-660-6853 for US domestic callers and + 1-201-612-7415 for international callers. The account number to access the replay is 3055 and the conference ID number is 350350.
About Zoom Technologies
Zoom Technologies is a holding company with subsidiaries that engage in the manufacturing, research and development, and sale of electronic and telecommunication products for 3rd generation mobile phones, wireless communication circuitry, and related software products. Zoom Technologies' subsidiary, Jiangsu Leimone, owns a majority stake of TCB Digital, which offers highly customized and high quality Electronic Manufacturing Service (EMS) for Original Equipment Manufacturer (OEM) customers as well as its own brand under the brand name of Leimone. The company's products are both exported and sold domestically. For more information about Zoom Technologies please visit Zoom's corporate website at http://www.zoomleimone.com
Keryx Rises as Phase III Zerenex Study Readies to Leave the Gate
By Donna Young
Washington Editor
Published May 7, 2010
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=54457
Investors Thursday drove shares of Keryx Biopharmaceuticals Inc. up 6.8 percent after the firm said it started a short-term Phase III study evaluating Zerenex (ferric citrate), an iron-based phosphate binder, as a treatment for hyperphosphatemia in dialysis patients with end-stage renal disease (ESRD).
Shares of the New York-based biotech (NASDAQ:KERX) closed at $5.95, a gain of 38 cents.
The initiation of the short-term trial marks the commencement of Zerenex's registration program, which also consists of a 58-week long-term safety and efficacy study scheduled to start in the third quarter.
The program is being conducted under a special protocol assessment (SPA) agreed on with the FDA, noted Keryx CEO Ron Bentsur. (See BioWorld Today, Jan. 06, 2010).
For the short-term multicenter, randomized, open-label Phase III trial of Zerenex, Keryx plans to enroll about 150 hemodialysis patients, who must undergo a two-week washout period. The patients will then be randomized to receive a daily fixed dose of Zerenex at 1 g, 6 g or 8 g for 28 days.
The primary endpoint of the study is to demonstrate a dose response in the change of serum phosphorous from baseline to the end of the treatment period, or day 28.
For its long-term multicenter, randomized, open-label, safety and efficacy Phase III trial of Zerenex, Keryx plans to enroll about 300 hemodialysis or peritoneal dialysis patients. That study will consist of a two-week washout period followed by a 52-week safety assessment, in which patients will be randomized at a 2:1 ratio to receive Zerenex or another phosphate binder.
The safety assessment will be followed by a four-week efficacy assessment. Only patients taking Zerenex during the safety assessment will be randomized to continue treatment on the drug or given a placebo during those four weeks.
Keryx plans to file a new drug application for Zerenex as a therapy for hyperphosphatemia in the first half of 2012, Bentsur told BioWorld Today.
He said he was "confident" that Zerenex - for which Keryx licensed the worldwide rights, excluding the Asian Pacific Region, from Panion & BF Biotech Inc. - would capture "meaningful market share" in the global phosphate binder space, which he noted is approaching $1.5 billion in sales.
Bentsur insisted that the drug has shown clear factors that differentiate it from currently marketed medicines to treat hyperphosphatemia in ESRD patients on dialysis, which include Genzyme Corp.'s Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate), Shire plc's Fosrenol (lanthanum carbonate) and Fresenius Medical Care North America's PhosLo (calcium acetate).
Fosrenol and PhosLo, Bentsur noted, have "overriding safety concerns."
In PhosLo's case, prescribers must be careful not to give too much of the drug because of the risk of hypercalcemia, or too much calcium in the blood. Fosrenol also carries risks of lanthanum accumulation, Bentsur said, adding that Zerenex does not come with those types of safety issues.
"So at a minimum, we think we could come in and be another alternative and take some additional market share away from those two," he said.
The "bigger prize," however, would be for Zerenex to cut into Renagel's and Renvela's market share, "which are by far the market leaders," Bentsur said, noting that his firm is targeting the "pill burden" of those two agents.
Patients on average must take up to 10 tablets per day of Renagel and Renvela, he noted, calling that a "pretty heavy" pill burden.
"It is a big issue that leads to noncompliance and inconvenience, which patients complain about all of the time," Bentsur said. "We think we can cut that quite substantially, perhaps by even as much as 40 to 50 percent," he argued, noting that Zerenex's tablet is the same size as Renagel and Renvela.
Renagel and Renvela, which are polymer-based products, also have gastrointestinal bloating associated with the drugs.
"We feel that we could have lower rates," Bentsur contended, insisting that Zerenex could provide a better safety, convenience and compliance profile than the two Genzyme drugs.
In addition, Bentsur said, as an iron-based drug, Zerenex also has shown other potential advantages over the currently marketed products.
He noted that ESRD patients on dialysis "without exception" will become iron-depleted to the point they will need intravenous iron or an erythropoiesis-stimulating agent (ESA).
In Keryx's long-term Phase II study of Zerenex, which Bentsur acknowledged was a "small" trial conducted outside of the U.S., the data showed that over time, patients on the treatment had "mild increases" in iron storage parameters, "which is what you want to see in these patients because they are iron-depleted."
Indeed, about 40 percent of the patients in the Phase II study were able to take I.V. iron and ESA holidays, he said.
"It ends up being a benefit to the patients because they are iron-depleted anyway, and they need iron," he said. "If we see that in the Phase III program, that could be a very big advantage for us. The pharmacoeconomic impact of something like that could be pretty tremendous," Bentsur added.
He insisted that the market was ripe for additional phosphate binders, such as Zerenex, "and we think this drug is very well-positioned to capture significant market share."
Now if Keryx can "just execute and meet our timelines and move forward," Zerenex has the potential to do just that, he said.
Keryx also recently started Phase III testing of its other lead compound perifosine in metastatic colorectal cancer and in multiple myeloma.
Those studies also are being conducted under SPA agreements with the FDA, Bentsur said.
"We are in a good position having two drugs pursuing three different Phase III programs all under SPAs," he said, adding that the company has sufficient capital to complete all three trials.
"I think that is a very compelling and unique position for a small biotech company to be in," Bentsur said. "We feel confident about the prospects of the company."
Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2010 Financial Results
Date : 05/10/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&article=42736521&symbol=KERX
Investor Conference Call to be held Tuesday, May 11, 2010 at 8:30am EDT
PR Newswire
NEW YORK, May 10
NEW YORK, May 10 /PRNewswire-FirstCall/ --
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease, today announced that a conference call will be held on Tuesday, May 11, 2010 at 8:30 a.m. EDT to discuss results for the first quarter ended March 31, 2010 and a business outlook for the remainder of 2010. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.
In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
Keryx will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
SOURCE Keryx Biopharmaceuticals, Inc.
ADDING MULTIMEDIA The Hartford Turns 200 Years Old
Date : 05/10/2010 @ 12:02PM
Source : Business Wire
Stock : The Hartford Financial Services Group, Inc. (HIG)
http://ih.advfn.com/p.php?pid=nmona&article=42742071&symbol=HIG
The Hartford Financial Services Group, Inc. (NYSE: HIG) today celebrates its 200th anniversary of helping its customers achieve what’s ahead. To commemorate the company’s May 10, 1810, incorporation date, CEO Liam E. McGee and CFO Christopher J. Swift will ring the opening bell at the New York Stock Exchange (NYSE).
“For 200 years, this iconic American company has helped its customers achieve what’s ahead, earning a reputation for trust, integrity and customer service excellence,” said McGee. “The company has played a critical role in America’s history, protecting and investing in the country’s trials and triumphs. We have assisted customers through almost every major historic event in the U.S. since 1810.”
The Hartford has been involved with numerous milestones in the nation’s history including:
* Providing the contract bonds for construction of the Hoover Dam in 1931 and the Golden Gate Bridge in 1937;
* Issuing a personal liability policy for President Dwight D. Eisenhower’s 190-acre working farm and insuring Abraham Lincoln’s home in Springfield, Ill., in 1861;
* Paying out almost $2 million in claims after the Great Chicago Fire of 1871 destroyed nearly 17,500 buildings and claimed 250 lives; and
* Paying more than 950 business, life, auto and property claims as a result of the September 11, 2001 terrorist attacks.
“As the company enters its third century, The Hartford is more committed than ever to its customers, agents and brokers, communities, shareholders and importantly, to our 28,000 teammates. We are well-positioned to move forward and have everything we need for success: a new strategy; a large and growing customer base; a broad and diverse product portfolio; and an enviable distribution network of agents, brokers and financial advisors. The Hartford’s goal is to deliver sustained, profitable growth over time with strength, confidence, focus and discipline,” said McGee.
“As the first insurance company incorporated in Connecticut, The Hartford has grown into one of the preeminent protection and wealth management companies in the United States,” said Connecticut Governor M. Jodi Rell. “I would like to congratulate The Hartford’s employees on 200 years of serving customers and for the remarkable impact they make in Connecticut and in the communities where the company’s employees live and work.”
Celebrating the Bicentennial
The Hartford has a full schedule of events and other activities to commemorate this historic milestone:
* Company leaders and employees will ring the opening bell on the morning of May 10 at the NYSE. There will be a display featuring the company’s Richard Childress Racing's No. 33 Chevrolet Impala with The Hartford’s commemorative logo. And, in honor of The Hartford’s role as the founding partner of the U.S. Paralympics, there will be curling, wheelchair basketball, and sit volleyball demonstrations at the NYSE.
* Bicentennial branded corporate advertising in major publications and online, featuring a celebratory gatefold ad in TIME magazine’s 100 Most Influential People issue, as well as graphics celebrating the company’s history on the homepage of the Wall Street Journal online and trade advertisements.
* In the spirit of the company’s longstanding commitment to philanthropy in the communities where employees live and work, The Hartford will sponsor employee community service programs and events in local markets across the country. In Hartford, the company and its employees raised more than $230,000 for Foodshare’s 2010 “Walk Against Hunger.” Thousands of employees are expected to participate in fundraising and volunteer activities with nonprofit organizations across the country to help their local communities achieve what’s ahead.
* Recognition programs for agents and partners, including philanthropic contributions in their honor, as well as other special events and activities.
Visit www.thehartford.com for more information on The Hartford’s bicentennial celebration, products and services. Multimedia from The Hartford's bicentennial events will also be posted to the company's social media pages throughout the month. Visit: http://www.facebook.com/thehartford, http://www.twitter.com/thehartford, http://www.youtube.com/thehartford and http://www.flickr.com/thehartford for the newest photos and videos. For additional multi-media elements, visit PressLift, http://thehartford.presslift.com.
About The Hartford
Celebrating 200 years of helping its customers achieve what’s ahead, The Hartford (NYSE: HIG) is an insurance and wealth management company. Through its unique focus on customer needs, the company serves businesses and consumers by providing the products and solutions they need to protect their assets and income from risks and manage their wealth and retirement needs. A Fortune 100 company, The Hartford is recognized widely for its service expertise and as one of the world's most ethical companies. More information on the company and its financial performance is available at www.thehartford.com.
HIG-C
Some of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ. These important risks and uncertainties include those discussed in our Annual Report for fiscal year 2009 on Form 10-K and the other filings we make with the Securities and Exchange Commission. We assume no obligation to update this release, which speaks as of the date issued.
NewCardio to Demonstrate the Innovative CardioBip at the Heart Rhythm Society Annual Meeting
Date : 05/07/2010 @ 8:00AM
Source : PR Newswire
Stock : Newcardio (BB) (NWCI)
http://ih.advfn.com/p.php?pid=nmona&article=42710914&symbol=NWCI
Heart Rhythm Society Guests Will Have the Opportunity to See and Use NewCardio's Unique and Patented Solution For Remote Wireless 12-lead Detection And Monitoring of Atrial Fibrillation and Myocardial Ischemia
PR Newswire
SANTA CLARA, Calif., May 7
SANTA CLARA, Calif., May 7 /PRNewswire-FirstCall/ --
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, will unveil its patented CardioBip™ technology for remote wireless 12-lead detection and monitoring of atrial fibrillation, ischemia and other cardiovascular events at the Heart Rhythm Society (HRS) 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.
NewCardio will be at booth number 2147, giving conference attendees the opportunity to learn about NewCardio's unique 3-D platform technology: CardioBip, a unique, hand-held device that provides an effective, solution for ECG remote monitoring; Cardio3KG™, advanced software which provides quantitative analyses of cardiac electrical activity, with improved sensitivity and specificity over the standard 12-lead ECG for diagnosis of acute coronary events; and QTinno™ , a software solution that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety in drug development. In addition, NewCardio personnel will be on-hand to demonstrate the CardioBip, both at the Company's booth and on May 13th in a suite at the Hyatt Regency Denver, adjacent to the Denver Convention Ctr where HRS is held. Session attendees can utilize the CardioBip on themselves to see first-hand the simplicity and effectiveness of the technology.
HRS is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. The Annual Scientific Sessions attract more than 9,000 professionals representing the allied specialties of cardiac pacing and cardiac electrophysiology. More information is available at http://www.hrsonline.org/Sessions/ on the internet.
Images of NewCardio's CardioBip are available on the internet at http://www.newcardio.com/products-cardio-bip.php.
NewCardio's CEO, Branislav Vajdic, PhD., commented, "CardioBip is the first remote, wireless, non-invasive device which provides accurate 12-lead ECG results, and as such we believe it will propel remote cardiac monitoring to an entirely new level. This is the culmination of several years of work to advance this technology, and we are excited to share this significant clinical and technological advancement with scientists, medical professionals and industry leaders at the HRS Annual Scientific Sessions. With its 3-D technology, CardioBip will provide important data that addresses significant problems with the diagnosis and treatment of chronic cardiac conditions."
In addition, and as previously announced, the HRS has accepted an abstract detailing the superior performance of NewCardio's CardioBip, particularly in patients with atrial fibrillation for its oral presentation. The abstract, titled "Three-dimensional Atrial Signal Reconstruction Facilitates Remote Detection Of Atrial Fibrillation," was written by Alexei Shvilkin, MD, PhD, Dejan Vukajlovic, MD, Vladan Vukcevic, MD, Ihor Gussak, MD, PhD, Bosko Bojovic, PhD, Uros Mitrovic, MS and Goran Simic, MS. The abstract discusses the use of CardioBip for improved atrial fibrillation (AF) monitoring and detection, highlighting a new AF detection algorithm based on NewCardio's proprietary 3-D ECG processing platform.
The CardioBip is a unique, hand-held device that provides a solution for ECG remote monitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop. What makes CardioBip unique is its extreme ease of use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs. The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device's electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms. The device is not currently approved for sale or distribution in the United States. On January 12, 2010, the U.S. Patent and Trademark Office issued patent 7,647,093, titled "Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing." This represents the core patent for CardioBip. Additional patent applications covering the CardioBip have been submitted.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hayden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio, Inc.
Cardium Bright Lights Conference Presentation - May 2010
05/11/10
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzgxMzM5fENoaWxkSUQ9MzgxNzY1fFR5cGU9MQ==&t=1
Cardium to Present at MDB Capital Group's 2010 Bright Lights Conference
07.05.2010 15:05
http://www.finanznachrichten.de/nachrichten-2010-05/16842707-cardium-to-present-at-mdb-capital-group-s-2010-bright-lights-conference-008.htm
SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) has been invited to present at the 2010 MDB Capital Group's Bright Lights Conference. The conference will be held May 10-12, 2010 at the Palace Hotel in San Francisco.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
Cardium's Chairman and Chief Executive Officer, Christopher J. Reinhard is presenting on Tuesday, May 11, 2010 and a copy of the presentation is available at the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.
The inaugural Bright Lights Conference will showcase 50 of the most innovative public companies ranked in the 90th percentile for technology leadership. The presenters were chosen from over 1,600 small cap companies with U.S. patents, as rated by PatentVest, MDB Capital Group's proprietary IP business intelligence database. The conference will include company presentations, expert panels, IP workshops and one-on-one investor meetings. Additionally, MDB Capital Group will provide analysis and objective data regarding the technology leadership and competitive landscape of the companies presenting during this exclusive, invitation-only event. For more information about the conference, visit http://www.mdb.com/bright-lights-conference.html.
About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at http://www.cardiumthx.com/.
Copyright 2010 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com/.
Cardium Therapeutics(TM) and Generx® and MedPodium(TM) are trademarks of Cardium Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellagen(TM), Excellarate(TM) and Osteorate(TM) are trademarks of Tissue Repair Company.
Photo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO
http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Cardium Therapeutics
CONTACT: Bonnie Ortega, Director, Investor/Public Relations of Cardium
Therapeutics, Inc., +1-858-436-1018, InvestorRelations@cardiumthx.com
Web Site: http://www.cardiumthx.com/
© 2010 PR Newswire
UPDATE -- The NASDAQ Stock Market Names Stocks With Cancelled Trades
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7730454
OfficeMax Inc
OMX | 5/7/2010 7:06:06 AM
The NASDAQ Stock Market Had No Technology or System Issues Associated With Yesterday's Trading Between 2:00 and 3:00 p.m. Eastern Time
NEW YORK, May 7, 2010 (GlobeNewswire via COMTEX News Network) --
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ), the world's largest exchange company, announced that The NASDAQ Stock Market had no technology or system issues associated with the trading that occurred between 2:00 and 3:00 p.m. ET yesterday. The NASDAQ Stock Market operated continuously and its close process ran successfully.
In addition, there is no indication at this time that a NASDAQ market participant experienced a technological failure in connection with this event. NASDAQ has coordinated a process among US Exchanges and therefore, pursuant to rule 11890(b), NASDAQ, on its own motion, will cancel all trades executed between 14:40:00 and 15:00:00 greater than or less than 60% away from the consolidated last print in that security at 14:40:00 or immediately prior. This decision cannot be appealed. NASDAQ has coordinated this decision with all other UTP Exchanges. NASDAQ will be canceling trades on the participant's behalf.
The stocks affected and the break points are posted on the following website: media.primezone.com/cache/6948/file/8212.pdf
About NASDAQ OMX
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,600 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx).
Cautionary Note Regarding Forward-Looking Statements
The matters described herein may contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about NASDAQ OMX's products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX's control. These factors include, but are not limited to, factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
Neither The NASDAQ OMX Group, Inc., nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investors should undertake their own due diligence and carefully evaluate companies before investing.
NDAQG
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: The NASDAQ OMX Group, Inc.
CONTACT: The NASDAQ OMX Group, Inc. Marisha Chinsky (646) 441-5258 marisha.chinsky@nasdaqomx.com Wayne Lee (301) 978-4875 wayne.d.lee@nasdaqomx.com Robert Madden (646) 441-5045 robert.madden@nasdaqomx.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
Company Name Change to CytoSorbents Corporation
MedaSorb Technologies Announces Company Name Change to CytoSorbents Corporation
Date : 05/06/2010 @ 6:18PM
Source : MarketWire
Stock : MedaSorb Technologies Corporation (MSBT)
http://ih.advfn.com/p.php?pid=nmona&article=42701834&symbol=MSBT
MONMOUTH JUNCTION, NJ -- (Marketwire)
05/06/10
MedaSorb Technologies Corporation, formerly trading under the symbol (OTCBB: MSBT), has formally changed its company name to CytoSorbents Corporation. Pursuant to the name change, effective at the open of business on May 7, 2010, the new ticker symbol for the Company will be (OTCBB: CTSO).
For additional information on the Company, please see our Form 10-K filed with the SEC on April 9, 2010 under our former name MedaSorb Technologies Corporation, which is available at www.sec.gov.
About CytoSorbents and CytoSorb?
CytoSorbents Corporation, and its operating subsidiary CytoSorbents, Inc., is a therapeutic device company in clinical trials to treat severe sepsis, often called "overwhelming infection," with a novel blood purification device called CytoSorb?. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body's abnormal immune response to the trigger that leads to the unregulated, massive production of cytokines, often called "cytokine storm," that then causes severe inflammation, organ failure and often death.. CytoSorb? is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped through the CytoSorb? cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using CytoSorb? to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb? in the European Union. CytoSorb? is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, treatment of rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company's website: www.cytosorbents.com
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.
Contact:
CytoSorbents Corporation
David Lamadrid
(732) 329-8885 ext. 816
davidl@cytosorbents.com
Evergreen Energy Strengthens Management Team with Hire of Chief Technology Officer
http://www.finanznachrichten.de/nachrichten-2010-05/16838700-evergreen-energy-strengthens-management-team-with-hire-of-chief-technology-officer-004.htm
07.05.2010 09:16
Evergreen Energy Strengthens Management Team with Hire of Chief Technology Officer
Evergreen Energy Inc. (NYSE Arca: EEE) has retained Michael Gionfriddo as its Chief Technology Officer. Gionfriddo will report to President and Chief Operating Officer Miles Mahoney, and will drive the technology strategy and development of the environmental intelligence solution, GreenCert™.
"With his extensive technology leadership experience in such organizations as Sun Microsystems and Juniper Networks, Michael offers a wealth of experience in leading software and engineering teams as well as building and implementing world-class architecture," stated Mahoney. "We continue to work closely on building our strategic relationships with industry leaders such as IBM, EIM and Black&Veatch. Michael will be instrumental in furthering and enhancing Evergreen's vision for and strategic development of our GreenCert product roadmap. His knowledge will help guide Evergreen to deliver timely marketable solutions that can evolve as this emerging market grows."
"The progress Evergreen has made in bringing GreenCert to market is very promising and I am excited to join the team at this pivotal time," stated Mr. Gionfriddo. "I see a great opportunity to innovate around the GreenCert platform and to leverage my experiences in developing world class solutions that are addressing global business challenges and problems. Additionally, I am excited about driving a cloud-based GreenCert solution for our customers."
Michael Gionfriddo was most recently a Distinguished Engineer and CTO of the Junos Space Business Unit at Juniper Networks. Prior to Juniper Networks, he was CTO of Enhanced Communication Delivery Systems (ECDS) where he was responsible for ECDS' ecENACT™ technology and strategy efforts. From 2003 to 2009, Mr. Gionfriddo was a Distinguished Engineer at Sun Microsystems and held a variety of technical leadership roles, with the most recent being CTO of Sun's rich Internet application platform, JavaFX™. Mr. Gionfriddo also held senior executive level roles with Rogue Wave Software, L7/EdeNET Communications and Lutris Technologies.
Evergreen Energy Inc.
Evergreen Energy Inc. (NYSE Arca: EEE) has developed two proven, proprietary, patented, and transformative green technologies: the GreenCert™ suite of software and services and K-Fuel®. GreenCert, which is owned exclusively by Evergreen, is a scientifically accurate, scalable environment intelligence solution that measures greenhouse gases and generates verifiable emissions credits. K-Fuel technology significantly improves the performance of low-rank coals yielding higher efficiency and lowering emissions. Visit www.evgenergy.com for more information.
Safe Harbor Statement
Statements in this release that relate to future plans or projected results of Evergreen Energy Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended by the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), and Section 21E of the Securities Exchange Act of 1934, as amended by the PSLRA, and all such statements fall under the "safe harbor" provisions of the PSLRA. Our actual results may vary materially from those described in any "forward-looking statement" due to, among other possible reasons, the realization of any one or more of the risk factors described in our annual or quarterly reports, or in any of our other filings with the Securities and Exchange Commission, all of which filings any reader of this release is encouraged to study. In addition, our ability to execute our business plan and develop the GreenCert™ or K-Fuel® technologies may be adversely impacted by the inability to complete the sale of Buckeye, raise significant additional capital or effectively complete any restructure transaction on a timely basis to fund our business operations. Readers of this release are cautioned not to put undue reliance on forward-looking statements.
Contacts:
Lippert / Heilshorn&Associates
Kirsten Chapman&Becky Herrick, 415-433-3777 (Evergreen Investors)
bherrick@lhai.com
© 2010 Business Wire
Euro-zone nations to finalize Greek rescue plan
Euro-zone nations to meet in Brussels to finalize Greek rescue plan
Friday May 7, 2010, 1:08 am EDT
http://finance.yahoo.com/news/Eurozone-nations-to-finalize-apf-2969554451.html?x=0&sec=topStories&pos=4&asset=&ccode=
BRUSSELS (AP) -- The 16 leaders of the euro zone meet in Brussels Friday to finalize the Greek rescue plan and assess how such financial crises can be avoided in the future. In Berlin, Germany's parliament will vote on its contribution to the loan package.
Greek lawmakers approved drastic austerity cuts Thursday needed to secure international rescue loans worth euro110 billion ($140 billion). Clashes briefly erupted in Athens in the streets outside parliament, forcing police to use tear gas.
In New York, the Dow Jones industrials plunged 1,000 points in less than half an hour on fears that Greece's debt problems could halt the global economic recovery. The Dow managed to recover two-thirds of its losses and close down 347 at 10,520.
The euro-zone nations have pledged to contribute euro80 billion ($100 billion) to the bailout plan for Greece over the next three years with the rest coming from the International Monetary Fund.
The 16 nations have pledged to make haste with the national approval of the funds and rescue package, hoping to have it finished for Friday's emergency summit. Major nations like Germany, France, Italy are likely to have concluded the process by then.
Germany, long Greece's toughest critic, was debating legislation that would provide the go-ahead to euro22.4 billion ($28.6 billion) in credit that Berlin wants to grant Athens.
It already passed the lower house's budget committee -- a day before Friday's vote by the full house.
The coalition led by Chancellor Angela Merkel has a comfortable majority in parliament and could pass the law without opposition help. Nonetheless, Finance Minister Wolfgang Schaeuble has asked the opposition for support.
Thursday's clashes in Athens came a day after violent protests left three people dead after a bank was firebombed in Athens.
Greek lawmakers voted 172-121 to approve the austerity measures -- worth about euro30 billion ($38.18 billion) through 2012 -- that will slash pensions and civil servants' pay and further hike consumer taxes.
The rescue loans are aimed at containing the debt crisis and keeping Greece's troubles from spreading to other countries with vulnerable state finances such as Portugal and Spain. The money will come from the IMF and the 15 other governments -- in addition to Greece -- whose countries use the euro.
Fears of Greek default have undermined the euro, and while the current package should keep Greece from immediate bankruptcy, its long-term prospects are unclear. The country's growth prospects are weak, and the population's willingness to accept cutbacks may wane, leading some economists to predict an eventual debt restructuring somewhere down the road.
There were reports that the Dow's sudden drop Thursday was caused by a trader who mistyped an order to sell a large block of stock. The drop in that stock's price was enough to trigger "sell" orders across the market.
Still, the Dow was already down more than 200 points as traders watched protests in the streets of Athens on TV.
Opposition parties lambasted the government for imposing measures that are too harsh for the population to bear.
"The dose of the medicine you are administering is in danger of killing the patient," conservative opposition leader Antonis Samaras said.
Clashes in Athens broke out at the end of a main protest that drew tens of thousands of people as police pushed back a few thousand demonstrators outside parliament.
The violence was quickly contained with riot police firing tear gas at the protesters, who had earlier pelted them with stones, oranges and bottles. Several small fires burned in surrounding streets. No injuries or arrests were reported.
Prime Minister George Papandreou expelled three Socialist deputies who dissented in the vote, reducing the party's number of seats to 157 in the 300-member parliament. Samaras also expelled a dissenting lawmaker, former Foreign Minister Dora Bakoyannis, reducing his share of parliamentary seats to 90.
Obama briefed on Greece and Wall Street turbulence
Administration pledges support for Greece while market regulators launch trading investigation
Thursday May 6, 2010, 8:28 pm EDT
http://finance.yahoo.com/news/Obama-briefed-on-Greece-and-apf-4098393791.html?x=0&sec=topStories&pos=1&asset=&ccode=
WASHINGTON (AP) -- The Obama administration stressed Thursday that it supports efforts to provide emergency loans to Greece, while U.S. market regulators announced an investigation into unusual trading activity during a volatile day on Wall Street.
Treasury Secretary Timothy Geithner and Lawrence Summers, head of the president's National Economic Council, briefed President Barack Obama on the market turbulence and the debt situation in Greece, White House press secretary Robert Gibbs said.
"Greece is enacting major economic reforms with the support of the euro-area and the IMF," Gibbs said in a statement. "We strongly support this effort to help restore stability to Greece and confidence to the global financial system and we will continue to communicate this to European officials."
A Treasury Department official said Geithner would discuss developments in Greece with other finance ministers from the Group of Seven major industrial countries during a conference call Friday morning. The G-7 includes the United States, Japan, Germany, France, Britain, Italy and Canada.
Meanwhile, the Securities and Exchange Commission and the Commodity Futures Trading Commission issued a statement saying they are working with other financial regulators and the stock exchanges to "review the unusual trading activity that took place briefly this afternoon."
The two agencies said they would take appropriate steps along with the stock exchanges to protect investors.
"We will make public the findings of our review along with recommendations for appropriate actions," the SEC and CFTC said in their statement.
Rep. Paul Kanjorski, D-Pa., chairman of the House Financial Services subcommittee that oversees the SEC, sent a letter Thursday to agency Chairman Mary Schapiro asking for a "thorough examination" of the causes of the plunge and what changes may be needed to prevent future episodes.
Kanjorski also announced that his panel will hold a hearing Tuesday to examine the episode.
"Within a matter of minutes today, we faced a market that seemed just as volatile as it did in the fall of 2008," Kanjorski told Schapiro in the letter. "Reports have surfaced that much of this movement was potentially as a result of a computer glitch. We cannot allow a technological error to spook the markets and cause panic."
The Treasury official, who spoke on the condition of anonymity because he was not authorized to speak publicly, said that the Friday call with Geithner and the other G-7 officials is aimed at getting an update on efforts to supply Greece with emergency loans from various European countries and the International Monetary Fund.
The official said Geithner also conferred with financial regulators in two conference calls to assess the sharp swings in stock prices Thursday afternoon.
Those discussions included Federal Reserve Chairman Ben Bernanke, Schapiro, William Dudley, president of the New York Federal Reserve Bank, and Gary Gensler, head of the CFTC.
Geithner also spoke in a separate call with European Central Bank President Jean-Claude Trichet, the official said.
Nasdaq to Cancel All Trades of Stocks Moving More Than 60%
Last Updated: May 6, 2010 18:14 EDT
http://www.bloomberg.com/apps/news?pid=20601087&sid=ai9CehsZxjqA&pos=1
May 6 (Bloomberg) -- Nasdaq OMX Group Inc. said it will cancel all trades of stocks at prices that were 60 percent above or below the last price at 2:40 p.m. or immediately prior.
The exchange operator said in a statement it will cancel all trades "greater than or less than 60 percent away from the consolidated last print in that security at 14:40:00 or immediately prior."
Nasdaq said it coordinated the decision with all other exchanges.
Sunrise Senior Living Becomes an Authorized Validation Organization to Greatly Enhance Memory Care for More Than 10,000 Resident
Date : 05/06/2010 @ 6:30PM
Source : PR Newswire
Stock : Sunrise Senior Living (SRZ)
http://ih.advfn.com/p.php?pid=nmona&article=42701940&symbol=SRZ
Sunrise Senior Living Becomes an Authorized Validation Organization to Greatly Enhance Memory Care for More Than 10,000 Residents
New Training Will Significantly Expand Validation Method Expertise in the United States
PR Newswire
MCLEAN, Va., May 6
MCLEAN, Va., May 6 /PRNewswire/ --
Sunrise Senior Living (NYSE: SRZ) announced today that it has become an Authorized Validation Organization with the Validation Training Institute, a not-for-profit organization offering training and certification in the Validation Method used to care for individuals with Alzheimer's disease and other forms of dementia. Over the next few months, Sunrise professional caregivers will begin certification training in the Validation Method to be used in the Company's more than 360 communities. Sunrise's recognition as a training center will greatly expand the number of trained caregivers using the Validation Method in the United States.
"Sunrise's long-standing commitment to excellent memory care and highly trained staff is unparalleled," said Mark Ordan, chief executive officer for Sunrise. "This opportunity to certify Sunrise team members sets a new standard for care in assisted living communities that deliver the dignity and respect deserved by seniors and their loved ones."
The Validation Method is a globally acclaimed protocol for care developed by Naomi Feil, M.S., A.C.S.W., who wrote her seminal book, Validation: The Feil Method in 1982. Her breakthroughs in dementia care take a holistic approach and are rooted in the understanding that unusual behaviors expressed by dementia sufferers are often due to a combination of cognitive, physical, and social losses, and represent an attempt to express unresolved feelings and emotions. Caregivers can deliver more ease, pleasure and dignity to those with dementia by using empathy to validate these individuals' desire to communicate.
"Sunrise Senior Living's new certification is a major milestone for the Validation Method in America," said Ms. Feil. "Their leadership will have an enormous positive impact on the quality of care for seniors with memory loss and on the quality of training for care providers."
Sunrise has long used techniques from the Validation Method to train team members and benefit its residents. This new opportunity for certification, however, will deepen its professional caregivers' understanding of the Validation Method and enhance their ability to care for residents as well as educate and support their family members.
Sunrise's flagship memory care program, called Reminiscence, provides a safe and stimulating environment for individuals to enjoy esteem-building activities. In recent years, the company has added Terrace Club, designed for residents with early stages of dementia, and Edna's Place, for residents in advanced stage of dementia.
"It is thrilling to be able to work more closely with Naomi Feil, whose groundbreaking work has taught us all that listening with empathy to those with dementia can reveal so much about our shared humanity," said Rita Altman, national director of Memory Care Services for Sunrise.
"Much of the frustration and anxiety of trying to care for those with dementia can be eliminated once caregivers understand how to reestablish the lines of communication," said Altman, who is one of only four Validation Masters in the world. "The Validation Method is also in keeping with Sunrise's principles of service – encouraging independence, enabling freedom of choice, preserving dignity, celebrating individuality, nurturing the spirit and involving family and friends – and will enhance what has already been established at Sunrise allowing us to truly improve the quality of life for our residents."
In 2009, Sunrise created a new position in each community called a "Life Enrichment Manager." The sole responsibility of these trained professionals is to work with memory care residents and their families to create activities that enrich residents' lives and keep their cognitive functions active.
"Our singular focus is on providing the services that best meet the needs of our residents – a focus that requires continual self-assessment, innovation and training," said Altman.
About Sunrise Senior Living
Sunrise Senior Living, a McLean, Va.-based company, employs approximately 40,000 people. As of March 31, 2010, Sunrise operated 365 communities in the United States, Canada, Germany and the United Kingdom, with a combined unit capacity of approximately 36,600 units. Sunrise offers a full range of personalized senior living services, including independent living, assisted living, care for individuals with Alzheimer's and other forms of memory loss, as well as nursing and rehabilitative services. Sunrise's senior living services are delivered by staff trained to encourage the independence, preserve the dignity, enable freedom of choice and protect the privacy of residents. To learn more about Sunrise, please visit http://www.sunriseseniorliving.com.
Contact:
Sara Krueger
Corporate Communications
(703) 744-1829
SOURCE Sunrise Senior Living